title: Nasal and pharyngeal resistance after topical mucosal vasoconstriction in normal humans.
abstract: Phenylephrine, an alpha-adrenergic agonist, increases pharyngeal cross-sectional area when applied topically to the nasal and pharyngeal mucosa, as determined by magnetic resonance imaging. In this study, we examined the possibility that the increase in area results from either a decrease in transmural collapsing pressure, as a result of a decrease in upstream (nasal) resistance, or an increase in upper airway muscle activity. In eight normal, awake men we measured inspiratory pharyngeal and nasal resistance and the electrical activity of the genioglossus (EMGGG) and alae nasi (EMG(AN) before and after pharyngeal and nasal + pharyngeal instillation of 1 ml of either 0.25% phenylephrine or normal saline; phenylephrine and saline were tested on separate days. Under control eucapnic conditions, pharyngeal resistance was 0.43 +/- 0.03 cm H2O/L/s, and nasal resistance was 2.43 +/- 0.14 cm H2O/L/s. Pharyngeal resistance was 0.29 +/- 0.03 cm H2O/L/s after nasal + pharyngeal instillation of phenylephrine and 0.98 +/- 0.13 cm H2O/L/s after saline; nasal resistance was 2.18 +/- 0.13 cm H2O/L/s after nasal + pharyngeal instillation of phenylephrine and 3.15 +/- 0.21 cm H2O/L/s after saline. Thus, phenylephrine decreased both nasal and pharyngeal inspiratory resistance. The change in pharyngeal resistance was not dependent on the change in nasal resistance. Eucapnic EMGGG and EMGAN activities did not change after phenylephrine or saline. We conclude that phenylephrine decreased pharyngeal resistance independent of a change in nasal resistance of upper airway muscle activity, and we believe that the changes in resistance we observed reflect a direct effect of phenylephrine on the pharyngeal mucosa and a consequent enlargement of pharyngeal size.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Physiology, Dartmouth Medical School, Hanover, New Hampshire 03756.
authors.forename: M J
authors.initials: MJ
authors.lastname: Wasicko
authors.forename: J C
authors.initials: JC
authors.lastname: Leiter
authors.forename: J S
authors.initials: JS
authors.lastname: Erlichman
authors.forename: R J
authors.initials: RJ
authors.lastname: Strobel
authors.forename: D
authors.initials: D
authors.lastname: Bartlett
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000403:Airway Resistance / Q000187:drug effects* / Q000502:physiology; D002404:Catheterization / Q000379:methods; D004576:Electromyography / Q000379:methods; D006801:Humans; D008297:Male; D009092:Mucous Membrane / Q000187:drug effects / Q000502:physiology; D009297:Nasal Mucosa / Q000187:drug effects* / Q000502:physiology; D009666:Nose; D010609:Pharyngeal Muscles / Q000187:drug effects / Q000502:physiology; D010614:Pharynx / Q000187:drug effects* / Q000502:physiology; D010656:Phenylephrine / Q000008:administration & dosage; D012016:Reference Values; D014661:Vasoconstriction / Q000187:drug effects* / Q000502:physiology
chemical_list: D010656:Phenylephrine